Five Fresh Insights into Tobacco Regulation from Mitch Zeller at 2015 NATO Show | CSPnet
Interesting read. Some good, some not but still some hope:
4. It's not an e-cig debate; it's a nicotine debate.
Zeller has often cited his position that the public health problem isn't nicotine, it's the delivery mechanism for the drug. During his panel, the director elaborated further on this notion.
"It shouldn't be a debate about e-cigs," he said. "It should be a debate about nicotine with e-cigs as the poster child of that debate."
Which isn't to say Zeller is fully on-board with nicotine being considered a low-risk drug.
"People have said we should treat nicotine like caffeine," said Zeller. "I'm not there yet, but I do agree we have to think about it differently."
5. Nicotine policy at forefront of things to come.
Perhaps the biggest clues Zeller dropped as to future priorities for the agency both centered on the continuum of risk: namely a discussion across multiple FDA centers on defining which nicotine-derived products should be regulated as tobacco and which should be regulated as therapeutic and an easier application process for products on the safer end of the risk continuum.
"Armed with more science, yes, future regulations should take into consideration a products' place on the continuum of risk," Zeller promised.
Interesting read. Some good, some not but still some hope:
4. It's not an e-cig debate; it's a nicotine debate.
Zeller has often cited his position that the public health problem isn't nicotine, it's the delivery mechanism for the drug. During his panel, the director elaborated further on this notion.
"It shouldn't be a debate about e-cigs," he said. "It should be a debate about nicotine with e-cigs as the poster child of that debate."
Which isn't to say Zeller is fully on-board with nicotine being considered a low-risk drug.
"People have said we should treat nicotine like caffeine," said Zeller. "I'm not there yet, but I do agree we have to think about it differently."
5. Nicotine policy at forefront of things to come.
Perhaps the biggest clues Zeller dropped as to future priorities for the agency both centered on the continuum of risk: namely a discussion across multiple FDA centers on defining which nicotine-derived products should be regulated as tobacco and which should be regulated as therapeutic and an easier application process for products on the safer end of the risk continuum.
"Armed with more science, yes, future regulations should take into consideration a products' place on the continuum of risk," Zeller promised.